Intrastriatal administration of 3-hydroxyglutaric acid induces convulsions and striatal lesions in rats

Brain Research

Volumn 916, Issue 1-2, 2001, Pages 70-75

  De Mello, Carlos F ^a   Kölker, Stefan ^b   Ahlemeyer, Barbara ^c   De Souza, Fabiane R ^a   Fighera, Michele R ^a   Mayatepek, Ertan ^b   Krieglstein, Josef ^c   Hoffmann, Georg F ^b   Wajner, Moacr ^d  

^a University of Santa Maria   (Brazil)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Excitotoxicity; Glutaric aciduria type I; NMDA receptor; Striatum

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 6,7 DINITRO 2,3 QUINOXALINEDIONE; CARBOXYLIC ACID; DIZOCILPINE; GLUTARIC ACID DERIVATIVE; GLUTARYL COENZYME A DEHYDROGENASE; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN INJURY; CELL DAMAGE; CONTROLLED STUDY; CONVULSION; CORPUS STRIATUM; DRUG EFFECT; EXPOSURE; GABAERGIC TRANSMISSION; IN VIVO STUDY; MALE; METABOLITE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NISSL STAINING; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; SENSORY STIMULATION; STEREOTAXIC SURGERY; STIMULATION; TISSUE SECTION;

ACYL COENZYME A; ANIMALS; BRAIN DISEASES, METABOLIC, INBORN; EXCITATORY AMINO ACID ANTAGONISTS; GABA AGONISTS; GLUTAMIC ACID; GLUTARATES; MALE; NEOSTRIATUM; NEUROTOXINS; RATS; RATS, WISTAR; RECEPTORS, AMPA; RECEPTORS, GABA-A; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES;

EID: 0035914179     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)02865-7     Document Type: Article

References (34)

1. Diagnosis and management of glutaric aciduria type I
2. Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric aciduria type 1
3. CT and MR of the brain in glutaric acidemia type I: A review of 59 published cases and a report of 5 new patients
4. Glutamate receptors in epilepsy
5. Ionic dependence of glutamate neurotoxicity
6. Neuroprotection by estrogens in a mouse model of focal ischemia and in cultured neurons: Evidence for a receptor-independent antioxidative mechanism
7. Intrastriatal methylmalonic acid administration induces rotational behavior and convulsions through glutamatergic mechanisms
8. Excitatory amino acid receptors in epilepsy
9. Glutaric aciduria: Biochemical and morphological considerations
10. Glutaryl-CoA dehydrogenase mutations in glutaric acidemia (type I): Review and report of thirty novel mutations
11. Assignment of human glutaryl-CoA dehydrogenase gene (GCDH) to the short arm of chromosome 19 (19p13.2) by in situ hybridization and somatic cell hybrid analysis
12. Neurological manifestations of organic acid disorders
13. Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency
14. Cerebral organic acid disorders induce neuronal damage via excitotoxic organic acids in vitro
15. Maturation-dependent neurotoxicity of 3-hydroxyglutaric and glutaric acids in vitro: A new pathophysiologic approach to glutaryl-CoA dehydrogenase deficiency
16. Evaluation of trigger factors of acute encephalopathy in glutaric aciduria type I: Fever and tumor necrosis factor-alpha
17. Contribution of reactive oxygen species to 3-hydroxyglutarate neurotoxicity in primary neuronal cultures from chick embryo telencephalons
18. Potentiation of 3-hydroxyglutarate neurotoxicity following induction of astrocytic iNOS in neonatal rat hippocampal cultures
19. Glutaric aciduria type I: An atypical presentation together with some observations upon treatment and the possible cause of cerebral damage
20. Biochemistry of glutaric aciduria type I: Activities of in vitro expressed wild-type and mutant cDNA encoding human glutaryl-CoA dehydrogenase
21. Pharmacological evidence for GABAergic and glutamatergic involvement in the convulsant and behavioral effects of glutaric acid
22. Excitatory amino acids as a final common pathway for neurologic disorders
23. The role of glutamate in epilepsy and other CNS disorders
24. Neurotransmission in epilepsy
25. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors
26. Brain lesions, obesity and other disturbances in mice treated with monosodium glutamate
27. Anticonvulsant activity of the NMDA antagonists, D(-)4-(3-phosphonopropyl) piperazine-2-carboxylic acid (D-CPP) and D(-) (E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid (D-CPPene) in a rodent and a primate model of reflex epilepsy
28. 3H]glutamate binding to plasma membranes from brain of young rats by glutaric acid in vitro
29. Inhibitory, GABAergic nerve terminate decrease at sites of focal epilepsy
30. AMPA receptors in epilepsy and as targets for antiepileptic drugs
31. In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci
32. Inhibition of brain glutamate decarboxylase by glutarate, glutaconate, and beta-hydroxyglutarate: Explanation of the symptoms in glutaric aciduria type I?
33. Glutaric aciduria type I: Pathomechanism of neurodegeneration
34. Mutation analysis in glutaric aciduria type I